Effects of Mycophenolate Mofetil (MMF) on Surrogate Markers for Cardiovascular Disease in HIV-1 Infected Patients
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study is a substudy of the MAN2 -study (Mycophenol mofetil in Antiretroviral Naïve
patients 2, see elsewhere in the ClinicalTrials.gov database). In the MAN2 study, HIV-1
infected patients who are not treated with antiretroviral treatment will be randomized to
treatment with Mycophenol mofetil (MMF)500 mg BID or a control group without treatment (open
label). Both patients randomized to treatment with MMF and patients randomized to the control
group will be asked to participate also in this substudy.
In this substudy we want to show whether monotherapy with Mycophenol mofetil (MMF) in
patients infected with HIV-1 can reduce acceleration of atherogenesis by attenuating various
inflammatory pathways normally involved in progression of atherosclerosis.
Phase:
Phase 4
Details
Lead Sponsor:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)